TriSalus Life Sciences (NASDAQ:TLSI) Trading Up 2% - Time to Buy?

Key Points

• Stock up 2% — TriSalus rose about 2% to $4.49 with a market capitalization of $275.3M, trading near its 50‑day SMA ($4.45) but below the 200‑day SMA ($5.20).
• Analyst consensus: Hold, $7.00 target — Ratings are mixed (one Buy, one Hold, one Sell) and the consensus price target is $7.00 after Canaccord cut its target from $12 to $7 while maintaining a buy.
• Small beat but still loss-making; insider selling — The company slightly beat quarterly estimates (EPS $‑0.12 vs. $‑0.13; revenue $13.21M vs. $13.20M), but analysts forecast a full‑year loss of about $1.55 per share, and CEO Mary Szela sold 15,944 shares as insiders trimmed positions while institutional ownership remains low (~2.6%).

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report)'s stock price rose 2% during trading on Wednesday . The company traded as high as $4.50 and last traded at $4.49. Approximately 163,177 shares traded hands during trading, a decline of 8% from the average daily volume of 177,035 shares. The stock had previously closed at $4.40.

Wall Street Analyst Weigh In

TLSI has been the subject of a number of analyst reports. Canaccord Genuity Group reduced their price objective on shares of TriSalus Life Sciences from $12.00 to $7.00 and set a "buy" rating for the company in a report on Friday, March 6th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of TriSalus Life Sciences in a report on Friday, April 10th. Zacks Research upgraded TriSalus Life Sciences from a "strong sell" rating to a "hold" rating in a research note on Tuesday, December 16th. Finally, Wall Street Zen upgraded TriSalus Life Sciences from a "sell" rating to a "hold" rating in a research note on Saturday, March 7th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $7.00.

TriSalus Life Sciences Stock Up 2.0%

The business has a 50-day simple moving average of $4.45 and a two-hundred day simple moving average of $5.20. The stock has a market capitalization of $275.26 million, a P/E ratio of -2.45 and a beta of 0.54.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.01. The company had revenue of $13.21 million during the quarter, compared to the consensus estimate of $13.20 million. On average, sell-side analysts forecast that TriSalus Life Sciences, Inc. will post -1.55 earnings per share for the current year.

Insiders Place Their Bets

In other TriSalus Life Sciences news, CEO Mary T. Szela sold 15,944 shares of the company's stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $3.85, for a total value of $61,384.40. Following the sale, the chief executive officer directly owned 752,987 shares in the company, valued at $2,898,999.95. This represents a 2.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold 30,150 shares of company stock valued at $119,849 in the last quarter. Corporate insiders own 16.30% of the company's stock.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of large investors have recently bought and sold shares of the business. Invesco Ltd. bought a new stake in TriSalus Life Sciences during the 4th quarter worth approximately $72,000. Man Group plc bought a new stake in TriSalus Life Sciences during the 4th quarter worth approximately $102,000. Abel Hall LLC bought a new stake in TriSalus Life Sciences during the 4th quarter worth approximately $73,000. Kotler Kevin bought a new stake in TriSalus Life Sciences during the 4th quarter worth approximately $1,013,000. Finally, Price T Rowe Associates Inc. MD bought a new stake in TriSalus Life Sciences during the 4th quarter worth approximately $104,000. 2.58% of the stock is currently owned by institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company's pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.